Calidi (CLDI) Biotherapeutics announced that it intends to offer to sell shares of its common stock in an public offering. All of the shares of common stock are to be sold by the company. Calidi intends to use the net proceeds from the offering for working capital and for general corporate purposes. Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent for the offering.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CLDI:
- Calidi files to sell 6.94M shares of common stock for holders
- Calidi Biotherapeutics Reveals Promising Virotherapy Data
- Calidi presents data on RTNova systemic technology in metastatic lung cancer
- Calidi prices 4.4M shares at $1.69 in public offering
- Calidi 4.44M share Spot Secondary priced at $1.69
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
